Search hospitals > Florida > Clearwater
Gastro Florida
Claim this profileClearwater, Florida 33756
Global Leader in Ulcerative Colitis
Global Leader in Crohn's Disease
Conducts research for Colitis
Conducts research for Nonalcoholic Steatohepatitis
Conducts research for Non-alcoholic Fatty Liver Disease
45 reported clinical trials
3 medical researchers
Summary
Gastro Florida is a medical facility located in Clearwater, Florida. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Colitis, Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease and other specialties. Gastro Florida is involved with conducting 45 clinical trials across 34 conditions. There are 3 research doctors associated with this hospital, such as Michael Weiss, Tejinder Glamour, MD, and Umesh Choudhry.Top PIs
Michael WeissGastro Florida4 years of reported clinical research
Studies Crohn's Disease
Studies Brain Anoxia Ischemia
7 reported clinical trials
8 drugs studied
Tejinder Glamour, MDWest Central Gastroenterology d/b/a Gastro Florida1 year of reported clinical research
Studies Ulcerative Colitis
Studies Colitis
3 reported clinical trials
2 drugs studied
Umesh ChoudhryWest Central Gastroenterology d/b/a Gastro Florida4 years of reported clinical research
Studies Crohn's Disease
2 reported clinical trials
2 drugs studied
Clinical Trials running at Gastro Florida
Ulcerative Colitis
Crohn's Disease
Clostridium Difficile Infection
Colitis
Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Diarrhea
Clostridium difficile infection
C. diff infection
Crohn's disease
Vedolizumab
for Ulcerative Colitis and Crohn's Disease
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.
Recruiting3 awards Phase 42 criteria
Etrasimod
for Ulcerative Colitis
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod. All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer. The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.
Recruiting1 award N/A3 criteria
RO7790121
for Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Recruiting1 award Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Gastro Florida?
Gastro Florida is a medical facility located in Clearwater, Florida. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Colitis, Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease and other specialties. Gastro Florida is involved with conducting 45 clinical trials across 34 conditions. There are 3 research doctors associated with this hospital, such as Michael Weiss, Tejinder Glamour, MD, and Umesh Choudhry.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.